高密度脂蛋白胆固醇对脓毒症患者并发急性肾损伤的影响
Effect of High-Density Lipoprotein Cholesterol (HDL-C) on Concurrent Acute Kidney Injury (AKI) in Patients with Sepsis
DOI: 10.12677/ACM.2023.13122727, PDF,   
作者: 古丽吉乃提·阿西木*:新疆医科大学研究生院,新疆 乌鲁木齐;麦迪那姆·图尔荪:新疆医科大学第五附属医院呼吸与危重症医学科,新疆 乌鲁木齐;肖 东#:新疆自治区人民医院重症医学科,新疆 乌鲁木齐
关键词: 脓毒症急性肾损伤脓毒症相关急性肾损伤高密度脂蛋白胆固醇(HDL-C)Sepsis Acute Kidney Injury Sepsis-Related Acute Kidney Injury High-Density Lipoprotein Cholesterol (HDL-C)
摘要: 脓毒症(Sepsis)是由严重感染、休克、外伤及外科大手术所致的临床综合征,其本质是形成难以控制的炎症反应和免疫抑制的恶性循环,最终导致全身脏器功能衰竭,其病程进展迅速,导致的患者病死率高27%,是ICU患者死亡的主要原因。脓毒症进展过程中易并发MODS,其中最常见的并发症是急性肾损伤(acute kidney injury, AKI)。研究表明,脓毒症所引起的AKI已成为重症脓毒症患者死亡的主要因素,病死率较高,已成为重症医学所面临的难题之一。因此,在治疗脓毒症的同时,对脓毒症所引起的AKI早诊断及治疗是改善患者预后的关键因素。
Abstract: Sepsis is a clinical syndrome caused by infection, trauma, shock and major surgical surgery. In es-sence, it is a vicious circle of uncontrollable inflammatory reaction and immune suppression, which eventually leads to systemic organ failure. The course of the disease advances rapidly, leading to a high case fatality rate of 27%, which is the main cause of death in ICU patients. MODS is prone to occur during sepsis progression, and acute kidney injury (AKI) is one of the most common severe complications. Studies have shown that sepsis complicated with AKI is the primary factor of death of severe sepsis patients, and the case fatality rate of sepsis-related patients is 50%~70%, which has become a clinical problem in the field of severe disease medicine. Therefore, while actively treating sepsis, the early identification and intervention of AKI secondary to sepsis are the key factors to improve the prognosis of patients with sepsis.
文章引用:古丽吉乃提·阿西木, 麦迪那姆·图尔荪, 肖东. 高密度脂蛋白胆固醇对脓毒症患者并发急性肾损伤的影响[J]. 临床医学进展, 2023, 13(12): 19375-19380. https://doi.org/10.12677/ACM.2023.13122727

参考文献

[1] Adhikari, N.K., Fowler, R.A., Bhagwanjee, S. and Rubenfeld, G.D. (2010) Critical Care and the Global Burden of Criti-cal Illness in Adults. The Lancet, 376, 1339-1346. [Google Scholar] [CrossRef
[2] Gómez, H. and Kellum, J.A. (2016) Sepsis-Induced Acute Kidney Injury. Current Opinion in Critical Care, 22, 546-553. [Google Scholar] [CrossRef
[3] Bellomo, R., Kellum, J.A., Ronco, C., et al. (2017) Acute Kidney Injury in Sepsis. Intensive Care Medicine, 43, 816-828. [Google Scholar] [CrossRef] [PubMed]
[4] Ma, S., Evans, R.G., Iguchi, N., et al. (2019) Sepsis-Induced Acute Kidney Injury: A Disease of the Microcirculation. Microcirculation, 26, e12483. [Google Scholar] [CrossRef] [PubMed]
[5] Zhou, J., Bai, Y., Wang, X., et al. (2019) A Simple Risk Score for Predic-tion of Sepsis Associated-Acute Kidney Injury in Critically Ill Patients. Journal of Nephrology, 32, 947-956. [Google Scholar] [CrossRef] [PubMed]
[6] Schortgen, F. and Asfar, P. (2015) Update in Sepsis and Acute Kidney Injury 2014. American Journal of Respiratory and Critical Care Medicine, 191, 1226-1231. [Google Scholar] [CrossRef
[7] Hoste, E., Kellum, J.A., Selby, N.M., et al. (2018) Global Epi-demiology and Outcomes of Acute Kidney Injury. Nature Reviews Nephrology, 14, 607-625. [Google Scholar] [CrossRef] [PubMed]
[8] 徐大民, 杨莉. 脓毒症相关急性肾损伤[J]. 中国实用内科杂志, 2016, 36(6): 441-444.
[9] 蒋远霞. 高尿酸血症对脓毒症患者发生急性肾损伤的影响[D]: [硕士学位论文]. 南宁: 广西医科大学, 2020.
[10] 魏凯, 杨万杰. 脓毒症相关性急性肾损伤流行病学及发病机制研究进展[J]. 医学综述, 2016, 22(3): 473-476.
[11] Umbro, I., Gentile, G., Tinti, F., Muiesan, P. and Mitterhofer, A.P. (2016) Recent Advances in Pathophysiology and Biomarkers of Sepsis-Induced Acute Kidney Injury. Journal of Infection, 72, 131-142. [Google Scholar] [CrossRef] [PubMed]
[12] 陆惠芬, 李寒英, 赵勤英. 体检人群高密度脂蛋白水平与性别、年龄及常见慢性病的关系[J]. 浙江医学, 2005, 27(1): 66-67.
[13] Boden, W.E., Probstfield, J.L., Anderson, T., et al. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267. [Google Scholar] [CrossRef
[14] Rizzo, M., Otvos, J., Nikolic, D., et al. (2014) Subfractions and Subpopulations of HDL: An Update. Current Medicinal Chemistry, 21, 2881-2891. [Google Scholar] [CrossRef] [PubMed]
[15] Pajkrt, D., Doran, J.E., Koster, F., et al. (1996) Anti-inflammatory Effects of Reconstituted High-Density Lipoprotein during Human Endotoxemia. Journal of Experimental Medicine, 184, 1601-1608. [Google Scholar] [CrossRef] [PubMed]
[16] Lekkou, A., Mouzaki, A., Siagris, D., et al. (2014) Serum Lipid Pro-file, Cytokine Production, and Clinical Outcome in Patients with Severe Sepsis. Journal of Critical Care, 29, 723-727. [Google Scholar] [CrossRef] [PubMed]
[17] Hosseini, M. and Ramazani, J. (2016) Evaluation of Acute Physi-ology and Chronic Health Evaluation II and Sequential Organ Failure Assessment Scoring Systems for Prognostication of Outcomes among Intensive Care Unit’s Patients. Saudi Journal of Anaesthesia, 10, 168-173. [Google Scholar] [CrossRef
[18] Golucci, A.P.B.S., Marson, F.A.L., Ribeiro, A.F., et al. (2018) Lipidprofile Associated with the Systemic Inflammatory Response Syndrome and Sepsis in Critically Ill Patients. Nutri-tion, 55-56, 7-14. [Google Scholar] [CrossRef] [PubMed]
[19] Trinder, M., Boyd, J.H. and Brunham, L.R. (2019) Molecular Reg-ulation of Plasma Lipid Levels during Systemic Inflammation and Sepsis. Current Opinion in Lipidology, 30, 108-116. [Google Scholar] [CrossRef
[20] Singh, I.M., Shishehbor, M.H. and Ansell, B.J. (2007) High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA, 298, 786-798. [Google Scholar] [CrossRef] [PubMed]
[21] Hu, P., Chen, Y., Pang, J. and Chen, X.H. (2019) Association be-tween IL-6 Polymorphisms and Sepsis. Innate Immunity, 25, 465-472. [Google Scholar] [CrossRef] [PubMed]
[22] Rochwerg, B., Oczkowski, S.J., Siemieniuk, R., et al. (2018) Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Critical Care Medicine, 46, 1411-1420. [Google Scholar] [CrossRef